Compare · COR vs MEDS
COR vs MEDS
Side-by-side comparison of Cencora Inc. (COR) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $68.11B, about 21971.9x MEDS ($3.1M).
- Over the past year, COR is down 2.2% and MEDS is down 98.0% - COR leads by 95.8 points.
- COR has been more active in the news (22 items in the past 4 weeks vs 6 for MEDS).
- COR has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Cencora Inc.
- DataMeds AI Inc.
- Price
- $357.02-0.56%
- $0.59-19.51%
- Market cap
- $68.11B
- $3.1M
- 1M return
- +4.76%
- -77.82%
- 1Y return
- -2.21%
- -98.02%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 22
- 6
- Recent ratings
- 25
- 1
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest COR
- President & CEO Mauch Robert P. was granted 18,292 restricted stock units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S was granted 4,402 restricted stock units (SEC Form 4)
- Chief Financial Officer Boratto Eva C was granted 5,488 restricted stock units (SEC Form 4)
- SVP & Chief Accounting Officer Krikorian Lazarus was granted 3,216 restricted stock units (SEC Form 4)
- EVP, Chief Data & Info Officer Verma Pawan was granted 4,231 restricted stock units (SEC Form 4)
- President & CEO Mauch Robert P. converted options into 40,271 shares and covered exercise/tax liability with 17,405 shares, increasing direct ownership by 34% to 90,652 units (SEC Form 4) (tax liability)
- SVP & Chief Accounting Officer Krikorian Lazarus converted options into 3,386 shares and covered exercise/tax liability with 1,457 shares, increasing direct ownership by 13% to 16,948 units (SEC Form 4) (withholding tax)
- Executive Vice President Campbell Elizabeth S converted options into 17,190 shares and covered exercise/tax liability with 7,947 shares, increasing direct ownership by 45% to 29,682 units (SEC Form 4) (for withholding tax)
- EVP, Chief Data & Info Officer Verma Pawan converted options into 1,321 shares and covered exercise/tax liability with 676 shares, increasing direct ownership by 7% to 10,077 units (SEC Form 4) to satisfy tax liability
- President & CEO Mauch Robert P. converted options into 4,066 shares and covered exercise/tax liability with 1,673 shares, increasing direct ownership by 4% to 67,786 units (SEC Form 4) (for withholding tax)
Latest MEDS
- UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards